Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxart, Inc.VXRT · Entity 6654 | Director · President, Chief Exec Officer | March 17, 2023 | March 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxart, Inc.
Report date March 17, 2023 · Filed March 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 452,735 |
Ending reported balance
After 2023-03-17 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2023-03-17 · Grant · Acquired 100,000 · Balance 185,000 F1: Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023. Row 2 · 2023-03-17 · Grant · Acquired 92,735 · Balance 277,735 F1: Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023. Row 3 · 2023-03-17 · Grant · Acquired 175,000 · Balance 452,735 F3: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the vesting commencement date of February 2, 2023, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2033-03-16 | Direct | 400,000 |
Reported balance
After 2023-03-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-17 · Grant · Acquired 400,000 · Balance 400,000 F2: The shares subject to this stock option shall fully vest on December 8, 2023. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2033-03-16 | Direct | 750,000 |
Reported balance
After 2023-03-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-17 · Grant · Acquired 750,000 · Balance 750,000 F4: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on February 2, 2024, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on February 2, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023.
F2: The shares subject to this stock option shall fully vest on December 8, 2023.
F3: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the vesting commencement date of February 2, 2023, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date.
F4: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on February 2, 2024, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on February 2, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2023 Filed Mar 22, 2023 00:06 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001437749-23-007443 · rdgdoc.xml · derivative · entry 5 Floroiu Cezar Andrei · CIK 0001808794 · Director · President, Chief Exec Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2033-03-16 F4 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on February 2, 2024, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on February 2, 2027. Read SEC document |
| March 17, 2023 Filed Mar 22, 2023 00:06 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001437749-23-007443 · rdgdoc.xml · derivative · entry 4 Floroiu Cezar Andrei · CIK 0001808794 · Director · President, Chief Exec Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-03-16 F2 · derivative.exercise_date: The shares subject to this stock option shall fully vest on December 8, 2023. Read SEC document |
| March 17, 2023 Filed Mar 22, 2023 00:06 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007443 · rdgdoc.xml · nonDerivative · entry 3 Floroiu Cezar Andrei · CIK 0001808794 · Director · President, Chief Exec Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 452,735 F3 · shares: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the vesting commencement date of February 2, 2023, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| March 17, 2023 Filed Mar 22, 2023 00:06 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 92,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007443 · rdgdoc.xml · nonDerivative · entry 2 Floroiu Cezar Andrei · CIK 0001808794 · Director · President, Chief Exec Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,735 F1 · shares: Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023. Read SEC document |
| March 17, 2023 Filed Mar 22, 2023 00:06 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007443 · rdgdoc.xml · nonDerivative · entry 1 Floroiu Cezar Andrei · CIK 0001808794 · Director · President, Chief Exec Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 F1 · shares: Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 01:20 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 550,000 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0001437749-22-007739 · rdgdoc.xml · derivative · entry 2 Floroiu Cezar Andrei · CIK 0001808794 · Director · President, Chief Exec Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2032-03-27 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 28, 2023, the first anniversary of the date that the grant was approved by the board of directors, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 28, 2026. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 01:20 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-007739 · rdgdoc.xml · nonDerivative · entry 1 Floroiu Cezar Andrei · CIK 0001808794 · Director · President, Chief Exec Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 F1 · shares: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the grant date, so that the restricted stock units would be fully vested on the fourth anniversary of the grant date. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 20:22 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $6.27 | $0.00 |
DisclosureSEC source: 0001437749-21-015073 · rdgdoc.xml · derivative · entry 1 Floroiu Cezar Andrei · CIK 0001808794 · Director · President, Chief Exec Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common stock · 250,000 shares Expires 2031-03-24 F1 · date: The option grant was approved by the board of directors of Vaxart, Inc. on March 25, 2021, subject to stockholder approval of an amendment to the Vaxart, Inc. 2019 Equity Incentive Plan, under which the stock option was granted. Vaxart, Inc.'s stockholders approved the plan amendment on June 16, 2021. F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 25, 2022, the first anniversary of the date that the grant was approved by the board of directors, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 25, 2025. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:49 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 900,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001437749-20-013329 · rdgdoc.xml · derivative · entry 2 Floroiu Cezar Andrei · CIK 0001808794 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2030-06-14 F2 · derivative.exercise_date: The shares subject to this option shall vest as follows: (i) one-third if the Company achieves a per share closing price equal to $5.00 or more during any 10-consecutive trading days after the Grant Date but before November 30, 2020, or such later date as determined by the Board (the "Reference Date"), (ii) one-third if the Company achieves a per share closing price equal to $7.50 or more during any 10-consecutive trading days after the Grant Date but before the Reference Date, and (iii) one-third if the Company achieves a per share closing price equal to $10.00 or more during any 10-consecutive trading days after the Grant Date but before the Reference Date, in each case subject to continued employment. In the event a Change in Control occurs before the Reference Date, any unvested portion of the Performance-Based Option will vest in accordance with the above schedule based on the Company attaining the specified stock price immediately prior to the closing of such transaction. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:49 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 845,280 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001437749-20-013329 · rdgdoc.xml · derivative · entry 1 Floroiu Cezar Andrei · CIK 0001808794 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845,280 Underlying: Common Stock · 845,280 shares Expires 2030-06-14 F1 · derivative.exercise_date: The option vests over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date of June 15, 2020 (the "Grant Date") and the remaining shares subject to the option vesting in equal monthly installments over the next 36 months. The option is subject to accelerated vesting with respect to 50% of any then-unvested option shares upon a substantial strategic agreement, as determined by the Board, and to accelerated vesting in full in the event of a "Change in Control" (as defined under the Company's 2019 Equity Incentive Plan). Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:40 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 54,720 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001437749-20-012744 · rdgdoc.xml · derivative · entry 1 Floroiu Cezar Andrei · CIK 0001808794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,720 Underlying: Common Stock · 54,720 shares Expires 2030-04-12 F1 · date: The option grant was approved by the board of directors of Vaxart, Inc. on April 13, 2020, subject to stockholder approval of an amendment to the Vaxart, Inc. 2019 Equity Incentive Plan, under which the stock option was granted. Vaxart, Inc.'s stockholders approved the plan amendment on June 8, 2020. F2 · derivative.exercise_date: The shares subject to this option shall vest annually over three years from the vesting commencement date of April 13, 2020, the date of the grantee's appointment as a director of Vaxart, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.